MDPI and ACS Style
Leisch, M.; Pfeilstöcker, M.; Stauder, R.; Heibl, S.; Sill, H.; Girschikofsky, M.; Stampfl-Mattersberger, M.; Tinchon, C.; Hartmann, B.; Petzer, A.;
et al. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group. Cancers 2022, 14, 2459.
https://doi.org/10.3390/cancers14102459
AMA Style
Leisch M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Hartmann B, Petzer A,
et al. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group. Cancers. 2022; 14(10):2459.
https://doi.org/10.3390/cancers14102459
Chicago/Turabian Style
Leisch, Michael, Michael Pfeilstöcker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Bernd Hartmann, Andreas Petzer,
and et al. 2022. "Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group" Cancers 14, no. 10: 2459.
https://doi.org/10.3390/cancers14102459